




## Featured Case Study

### Recurrent Prostate Cancer



#### Patient History

- 80 y/o, 142 lb male with hx/of prostate cancer, PSA=4.6
- CT scan (+) for lung nodules; bone scan (-)

#### PET/CT Findings

- Increased FDG uptake in
- Right upper lobe nodule (fig. 1) SUV = 4.5
- Prostate gland (fig. 2) SUV = 4.4
- Multiple sclerotic bone locations
- Retroperitoneal and perirectal lymph nodes

#### Impression:

- Findings consistent with recurrent primary and metastatic prostate cancer.

#### Discussion:

Data has shown that FDG-PET imaging has a limited role in prostate cancer, particularly in diagnosis of primary disease. However, PET may be useful in detection of suspected recurrent prostate cancer in patients with rising PSA and other symptoms, and when other imaging tests are inconclusive. The case above shows multiple metastases that are FDG-avid in a patient with elevated PSA and negative bone scan. Early data from the NOPR (see right) shows a trend toward similar findings.

Findings and Impression reported by Arturo Lira, MD

www.tridentpet.com  
770-513-2499

## The Stage

December 2006

### Revolutionizing Cancer Care

Molecular Imaging is transforming the diagnosis and treatment of cancer. Due to the unique and invaluable information obtained we are now able to provide an earlier and more accurate diagnosis which results in more effective treatment for the patient and the ability to treat cancer with an unprecedented degree of efficacy.

Nowhere is the impact of molecular imaging more evident than what is transpiring with the National Oncologic PET Registry. NOPR, as it is commonly referred to, is a unique collaboration between industry and the Center for Medicare and Medicaid Services (CMS), who has moved toward an evidenced based reimbursement system using coverage with evidence development. This Registry allows for coverage and reimbursement of previously non-covered cancers. The data which is being collected will be used as a basis for the determination of further expansion of coverage for Medicare coverage for PET/CT imaging.



The initial results are significant and will be published early next year. Nationally, tens of thousands of studies have been performed and the change in intended management evaluated. Trident has performed over 200 NOPR studies, and in over 80% of the cases – most notably in prostate and ovarian cancer – there has been a change in intended management. We anticipate that the results at Trident are representative of what is happening nationally. These are remarkable statistics given that these indications were previously non-covered.

Trident Molecular Imaging is front and center stage in this revolution. With our 3<sup>rd</sup> year behind us, we will be announcing new initiatives which will reinforce our leadership and commitment to providing the highest quality PET/CT service possible to the physicians and patients we serve.

I would also like to take this time to wish you and your family a Merry Christmas and a Happy New Year.

Fred Stuvek, Jr.  
President & CEO  
Trident Molecular Imaging



## Medicare Coverage Policy for PET/CT Scans expands under the National Oncologic PET Registry (NOPR)\*

Medicare patients meeting the following criteria *will* be covered for\*

- Diagnosis
- Initial staging for metastases
- Monitoring effectiveness of ongoing Tx
- Re-staging for assessment of concluded Tx, and local or regional recurrence

### Cancers Previously Covered

Breast  
Cervical  
Colorectal  
Esophageal  
Head & Neck Cancers  
Non Sm Cell Lung  
Lymphoma  
Melanoma  
Solitary Pulm Nodule  
Thyroid

### NOPR Coverage\*

Unknown Primary  
Paraneoplastic Synd.  
Gastric  
Liver  
Gallbladder  
Pancreas  
Small Cell Lung  
Thymus  
Bone  
Male Breast  
Ovarian  
Prostate  
Testicular  
Penile  
Bladder  
Kidney  
Eye  
Sarcoma  
Myeloma  
Merkle Cell  
Other Not Listed

\*Medicare coverage as part of the National Oncologic PET Registry, which requires submission of pre- and post-PET data for each patient. Many private payers, including BCBS and UHC cover PET imaging for many of the above indications.

770-513-2499  
www.tridentpet.com

## The Stage

December 2006

### To Order a PET/CT Scan:


Call: 770-513-2499

Fax: 770-513-2715

Email:

infogwinnett@tridentpet.com

Trident PET of Gwinnett  
545 Old Norcross Road,  
Suite 200  
Lawrenceville, GA 30045



*"Quality Without Compromise"*